R3X1 Stock Chart & Stats
€4.82
<€0.01(0.29%)
At close: 4:00 PM EST
€4.82
<€0.01(0.29%)
Day’s Range― - ―
52-Week Range€0.89 - €4.84
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€283.46M
Enterprise Value€301.19M
Total Cash (Recent Filing)€59.96M
Total Debt (Recent Filing)€25.93M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 07, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding82,565,834
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)81.49
Price to Sales (P/S)88.10
P/FCF Ratio-35.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.76Price Target Upside102.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.98
Revenue Forecast (FY)€13.90M
Bulls Say, Bears Say
Bulls Say
Pipeline Breadth & First‑mover PositionOpus has a diversified IRD pipeline with five programs and several candidates advancing toward first-in-human studies. A multi-program portfolio spreads scientific and regulatory risk, increases the chance of clinical success and commercial upside, and supports sustained R&D momentum over the next 2–4 years.
Extended Funded Runway Into 2029The combination of roughly $100M cash, a $35M initial tranche and access to up to $155M in senior notes materially lengthens funding visibility. A multi-year runway reduces near-term refinancing pressure, allowing program execution and multiple clinical milestones to be achieved without immediate equity raises.
Milestone‑tied, Structured FinancingMilestone‑based tranches and limited conversion rights align capital disbursements with development progress, lowering the need for open-market equity issuance early. This structure preserves strategic optionality, better aligns investor incentives to clinical value creation, and tempers dilution risk over the program lifecycle.
Bears Say
Negative Stockholders' EquityNegative equity signals accumulated losses have exceeded contributed capital, weakening the company’s financial buffer. Over the medium term this limits ability to absorb setbacks, may restrict financing options, and requires either sustained profitable operations or fresh capital to restore a healthy balance sheet.
Persistent Cash BurnLarge, ongoing negative operating and free cash flow mean the business depends on external financing to continue development. Even with improved trends, the absolute cash outflows increase the probability of future dilution or additional secured financing, pressuring long-term capital efficiency.
Declining Revenue & Deep LossesA sharp revenue decline alongside a swing to large operating losses reflects instability in commercial or partner-derived income. Persistently negative margins reduce internal funding capacity and increase reliance on external capital, raising execution risk for multi-year clinical development plans.
Opus Genetics News
R3X1 FAQ
What was Opus Genetics, Inc.’s price range in the past 12 months?
Opus Genetics, Inc. lowest stock price was €0.89 and its highest was €4.84 in the past 12 months.
What is Opus Genetics, Inc.’s market cap?
Opus Genetics, Inc.’s market cap is €283.46M.
When is Opus Genetics, Inc.’s upcoming earnings report date?
Opus Genetics, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 26 days.
How were Opus Genetics, Inc.’s earnings last quarter?
Opus Genetics, Inc. released its earnings results on May 12, 2026. The company reported -€0.657 earnings per share for the quarter, missing the consensus estimate of -€0.117 by -€0.539.
Is Opus Genetics, Inc. overvalued?
According to Wall Street analysts Opus Genetics, Inc.’s price is currently Undervalued.
Does Opus Genetics, Inc. pay dividends?
Opus Genetics, Inc. does not currently pay dividends.
What is Opus Genetics, Inc.’s EPS estimate?
Opus Genetics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Opus Genetics, Inc. have?
Opus Genetics, Inc. has 82,565,834 shares outstanding.
What happened to Opus Genetics, Inc.’s price movement after its last earnings report?
Opus Genetics, Inc. reported an EPS of -€0.657 in its last earnings report, missing expectations of -€0.117. Following the earnings report the stock price went up 1.402%.
Which hedge fund is a major shareholder of Opus Genetics, Inc.?
Currently, no hedge funds are holding shares in DE:R3X1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opus Genetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.76 (102.47% Upside)
€9.76 (102.47% Upside)
Blogger Sentiment
Neutral
DE:R3X1 Sentiment 50%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth €6.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
250.00%
12-Months-Change
Fundamentals
Return on Equity
6068.79%
Trailing 12-Months
Asset Growth
38.66%
Trailing 12-Months
Company Description
Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
R3X1 Stock 12 Month Forecast
Average Price Target
€9.76
▲(102.47% Upside)
Technical Analysis
Ovid Therapeutics
―
Shattuck Labs
―
Inhibikase Therapeutics
―
Surrozen
―
Biomea Fusion
―
Options Prices
Currently, No data available
---